Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion
Schlieren (Zürich), Switzerland, December 2, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced that the first patient has been enrolled in its global ASTRA (Ankle Subtalar arThrodesis Randomized Assessment) study. ASTRA is a prospective, randomized, single-blinded, controlled, multi-center study to assess the safety and performance of MagnetOsTM compared to autograft (patient’s own bone) in patients undergoing hindfoot or ankle fusions. Subtalar fusion will be one of many surgical approaches included in the study.
The ASTRA study is part of Kuros’ expanding global extremities strategy and represents the company’s continued commitment to building high-quality clinical evidence across a variety of surgical applications. This international study will include sites in the U.S., Australia, New Zealand, Europe and/or the Middle East.
Approximately 126 patients undergoing hindfoot or ankle fusions will be prospectively enrolled and randomized to receive treatment in either the MagnetOs arm (MagnetOs Putty or MagnetOs Easypack Putty used standalone, not mixed with other bone grafting materials) or the autograft arm. This study is registered on ClinicalTrials.gov under identifier: NCT07225751.
Chris Fair, Chief Executive Officer of Kuros Biosciences, stated: “Enrollment of the first patient in the ASTRA trial marks another important milestone in our Kuros mission to expand the clinical reach of MagnetOs. Building on the strength of our ongoing Level I PROOF and PRECISE clinical trials in posterolateral spine fusion, ASTRA extends our clinical evidence portfolio into foot and ankle. We’re proud to continue advancing the science of bone healing into new anatomical regions where surgeons need reliable solutions for their patients.”
“We’re excited to participate and get the enrollment underway in this important global study,” said Dr. Jesse Doty, Orthopedic Surgeon and Principal Investigator at Erlanger Orthopaedics in Chattanooga, Tennessee. “Successful bone fusion in complex hindfoot and ankle procedures can be challenging, especially when autograft availability or quality is limited. I’m excited to be a part of this Level I study looking at the efficacy of a novel advanced bone graft in my hindfoot fusion patients.”
The study name ASTRA was inspired by astragalus, the historical term for what is now known as the talus or ankle bone, underscoring the study’s focus on improving outcomes in ankle and hindfoot fusion procedures.